• 1
    Stupp R,Mason WP,Van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987996.
  • 2
    Mirimanoff R,Mason W,Van den Bent M, et al. Is long-term survival in glioblastoma possible? Updated results of the EORTC/NCIC Phase III randomized trial on radiotherapy and concomitant and adjuvant temozolomide versus RT alone [abstract]. Int J Radiat Oncol Biol Phys. 2007; 69( suppl 5): 52 .
  • 3
    Hegi M,Diserens A-C,Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 9971003.
  • 4
    Gorlia T,Van den Bent M,Hegi M, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE. 3. Lancet Oncol. 2008; 9: 2938.
  • 5
    Butowski NA,Sneed P,Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. 2006; 24: 12731280.
  • 6
    Kerbel RS,Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4: 423426.
  • 7
    Bertolini F,Paul S,Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003; 63: 43424346.
  • 8
    Zhou Q,Guo P,Wang X, et al. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther. 2007; 321: 265275.
  • 9
    Mason WP,Del Maestro R,Eisenstat D, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007; 14: 110117.
  • 10
    Kandel MJ,Loehr A,Harter P,Traut A,Gravert K,duBois A. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatinum hypersensitivity. Int J Gynecol Cancer. 2005; 15: 780784.
  • 11
    Yeoh C,Chau I,Cunningham D,Norman AR,Hill M,Ross PJ. Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from 3 consecutive randomized controlled trials. Clin Colorectal Cancer. 2003; 3: 102197.
  • 12
    Liu L,Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006; 12: 328331.
  • 13
    Tolcher AW,Gerson SL,Denis L, et al. Marked inactivation of O6-alkylguanine-DNA-alkyltansferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88: 10041011.
  • 14
    Macdonald DR,Cascino TL,Schold SC,Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 12771280.
  • 15
    Franceschi E,Omuro A,Lassman A, et al. Salvage temozolomide for prior temozolomide responders. Cancer. 2005; 104: 24732476.
  • 16
    Jauch T,Hau P,Bogdahn U. Re-challenge with temozolomide (TMZ) at recurrence in high-grade gliomas. Proc ASCO. 2007; 25( 18 suppl): 83s.
  • 17
    Kong DS,Lee JI,Kim WS, et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep. 2006; 16: 11171121.
  • 18
    Su YB,Sohn S,Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004; 22: 610616.